| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2017 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.